Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Fed Regist ; 67(90): 31123-5, 2002 May 09.
Artigo em Inglês | MEDLINE | ID: mdl-12001971

RESUMO

The Food and Drug Administration (FDA) is issuing a final rule stating that a certain ingredient in over-the-counter (OTC) drug products is not generally recognized as safe and effective or is misbranded. FDA is issuing this final rule after considering the reports and recommendations of various OTC drug advisory review panels and public comments on proposed agency regulations. This final rule addresses the ingredient octoxynol 9, considered in the rulemaking for OTC vaginal contraceptive drug products. Based on the failure of interested parties to submit new data or information to FDA under the proposed regulation, the agency has determined that the presence of this active ingredient in an OTC drug product would result in that drug product not being generally recognized as safe and effective for its intended use or would result in misbranding. This final rule is part of FDA's ongoing OTC drug product review.


Assuntos
Qualidade de Produtos para o Consumidor/legislação & jurisprudência , Anticoncepcionais Femininos/classificação , Medicamentos sem Prescrição/classificação , Octoxinol/classificação , Aprovação de Drogas/legislação & jurisprudência , Rotulagem de Medicamentos/classificação , Rotulagem de Medicamentos/legislação & jurisprudência , Humanos , Espermicidas/classificação , Estados Unidos , United States Food and Drug Administration
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA